|Company name||Akari Therapeutics, Plc|
|Class period||March 30, 2017 and May 11, 2017|
|Lead plaintiff deadline||July 11, 2017|
|Court||Southern District of New York|
NEW YORK, May 16, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who acquired Akari Therapeutics, Plc (NASDAQ: AKTX) securities between March 30, 2017 and May 11, 2017 (the “Class Period”).
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose that: Chief Executive Officer Dr. Gur Roshwalb and possibly other executives were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; that Akari lacked adequate checks and protections to prevent such behavior; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On May 11, 2017, Akari announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and subsequently withdrawn in April 26, 2017 by Edison Investment Research Ltd. When this information was released, Akari shares lowered in value materially, which harmed investors according to the Complaint.
If you purchased or otherwise acquired Akari securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.